Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Outlook Therapeutics, Inc.

Market Cap 147M 127M 117M 110M 206M 14.02B 209M 1.39B 540M 6.82B 553M 542M 23.62B P/E Ratio 2026 *
-2.3x
P/E Ratio 2027 * -4.57x
Enterprise Value 147M 127M 117M 110M 206M 14.02B 209M 1.39B 540M 6.82B 553M 542M 23.62B EV / Sales 2026 *
123x
EV / Sales 2027 * 3.22x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day+2.05%
1 week+57.07%
Current month+67.12%
1 month+403.09%
3 months+189.79%
6 months-38.38%
Current year-22.78%
1 week 0.68
Extreme 0.6752
1.31
1 month 0.22
Extreme 0.215
1.31
Current year 0.16
Extreme 0.1611
1.31
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37.2
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 2025-06-30
Chief Executive Officer 60 2024-12-02
Chief Tech/Sci/R&D Officer - 2023-01-18
Director TitleAgeSince
Director/Board Member 60 2018-08-01
Director/Board Member 65 2015-12-10
Chairman 41 2025-01-30
Date Insider Type Main position Quantity % Market Cap.
06-01Buy

Director

29,000 0.0195%
05-27
Gms Ventures & Investments
BuyCompany 39,516,849 26.5951%
05-26Buy

Chairman

122,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
+10.91%+57.07%-33.70%-96.30% 133M
-0.35%+0.97%-15.96%-12.73% 42.96B
+3.11%+3.11%+274.29%+507.94% 31.73B
+0.22%-1.08%+14.03%-14.37% 30.22B
+1.62%-2.08%-4.36%+24.05% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.63%+2.88%+53.73%+114.36% 13.57B
-0.40%-1.29%+6.06%+7.59% 12.96B
+1.14%+3.62% - - 13.39B
-0.74%-1.62%+105.71%+76.01% 12.2B
Average +0.91%+4.42%+45.76%+69.33% 21B
Weighted average by Cap. +1.02%+0.72%+54.40%+95.69%

Financials

2026 *2027 *
Net sales 1.2M 1.04M 955K 894K 1.68M 114M 1.7M 11.28M 4.4M 55.52M 4.5M 4.41M 192M 45.73M 39.49M 36.39M 34.07M 63.84M 4.35B 64.83M 430M 168M 2.12B 172M 168M 7.33B
Net income -53.46M -46.17M -42.55M -39.83M -74.64M -5.08B -75.8M -502M -196M -2.47B -201M -196M -8.56B -35.61M -30.76M -28.34M -26.53M -49.72M -3.38B -50.49M -335M -130M -1.65B -134M -131M -5.7B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26-06-12 1.220 $ +10.91% 37,791,865
26-06-11 1.100 $ +23.60% 43,930,129
26-06-10 0.8900 $ +26.29% 23,160,981
26-06-09 0.7047 $ -2.40% 7,587,249
26-06-08 0.7220 $ -7.04% 8,661,563
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.220USD
Average target price
5.500USD
Spread / Average Target
+350.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!